Neal Shore

Summary

Publications

  1. doi request reprint Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer
    Neal D Shore
    Carolina Urologic Research Center, Myrtle Beach, South Carolina Electronic address
    J Urol 195:612-8. 2016
  2. doi request reprint Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study
    Neal D Shore
    Carolina Urologic Research Center, Myrtle Beach, SC, USA Electronic address
    Lancet Oncol 17:153-63. 2016
  3. doi request reprint Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective
    Neal D Shore
    Department of Urology, Carolina Urologic Research Center, Myrtle Beach, SC Electronic address
    Urology 85:717-24. 2015
  4. doi request reprint A urologic oncology roundtable discussion: the role of disease monitoring in treatment decision-making for patients with metastatic castration-resistant prostate cancer
    Neal D Shore
    Carolina Urologic Research Center, Myrtle Beach, SC
    Hosp Pract (1995) 41:78-80. 2013
  5. doi request reprint Chemotherapy for prostate cancer: when should a urologist refer a patient to a medical oncologist?
    N D Shore
    Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA
    Prostate Cancer Prostatic Dis 16:1-6. 2013
  6. ncbi request reprint Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer
    Neal D Shore
    Carolina Urologic Research Center Atlantic Urology Clinics, Myrtle Beach, SC 29572, USA
    Cancer Control 20:7-16. 2013
  7. doi request reprint New developments in castrate-resistant prostate cancer
    N Shore
    Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC 29572, USA
    BJU Int 109:22-32. 2012
  8. doi request reprint Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer
    Neal Shore
    Carolina Urologic Research Center Atlantic Urology Clinics, Myrtle Beach, SC 29572, USA
    BJU Int 109:226-32. 2012
  9. doi request reprint Testosterone in prostate cancer: the Bethesda consensus
    Bob Djavan
    Department of Urology, New York University School of Medicine, New York, NY, USA
    BJU Int 110:344-52. 2012
  10. doi request reprint Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer
    Neal Shore
    Carolina Urologic Research Center, Myrtle Beach, SC, USA
    Curr Med Res Opin 30:547-53. 2014

Detail Information

Publications10

  1. doi request reprint Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer
    Neal D Shore
    Carolina Urologic Research Center, Myrtle Beach, South Carolina Electronic address
    J Urol 195:612-8. 2016
    ..We present the results from PROCEDE-1000, a large, prospective registry designed to evaluate the impact of the cell cycle progression test on shared treatment decision making for patients newly diagnosed with prostate cancer...
  2. doi request reprint Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study
    Neal D Shore
    Carolina Urologic Research Center, Myrtle Beach, SC, USA Electronic address
    Lancet Oncol 17:153-63. 2016
    ..The objective of the TERRAIN study was to compare the efficacy and safety of enzalutamide with bicalutamide in patients with metastatic castration-resistant prostate cancer...
  3. doi request reprint Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist's perspective
    Neal D Shore
    Department of Urology, Carolina Urologic Research Center, Myrtle Beach, SC Electronic address
    Urology 85:717-24. 2015
    ..8 months. This article summarizes current guidelines and clinical studies that led to the approval of radium-223 as an overall survival therapy, and discusses the urologist's perspective on using radium-223 in clinical practice. ..
  4. doi request reprint A urologic oncology roundtable discussion: the role of disease monitoring in treatment decision-making for patients with metastatic castration-resistant prostate cancer
    Neal D Shore
    Carolina Urologic Research Center, Myrtle Beach, SC
    Hosp Pract (1995) 41:78-80. 2013
    ....
  5. doi request reprint Chemotherapy for prostate cancer: when should a urologist refer a patient to a medical oncologist?
    N D Shore
    Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC, USA
    Prostate Cancer Prostatic Dis 16:1-6. 2013
    ....
  6. ncbi request reprint Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer
    Neal D Shore
    Carolina Urologic Research Center Atlantic Urology Clinics, Myrtle Beach, SC 29572, USA
    Cancer Control 20:7-16. 2013
    ....
  7. doi request reprint New developments in castrate-resistant prostate cancer
    N Shore
    Carolina Urologic Research Center, Atlantic Urology Clinics, Myrtle Beach, SC 29572, USA
    BJU Int 109:22-32. 2012
    ..The mechanism of action of these and other promising agents are discussed alongside current therapeutic options and their potential place in the treatment landscape for CRPC is considered...
  8. doi request reprint Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer
    Neal Shore
    Carolina Urologic Research Center Atlantic Urology Clinics, Myrtle Beach, SC 29572, USA
    BJU Int 109:226-32. 2012
    ..To evaluate the efficacy and tolerability of a once-yearly histrelin implant during an open-label extension of a pivotal study...
  9. doi request reprint Testosterone in prostate cancer: the Bethesda consensus
    Bob Djavan
    Department of Urology, New York University School of Medicine, New York, NY, USA
    BJU Int 110:344-52. 2012
    ..This is especially important when PCa progresses from an endocrine to an intracrine status...
  10. doi request reprint Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer
    Neal Shore
    Carolina Urologic Research Center, Myrtle Beach, SC, USA
    Curr Med Res Opin 30:547-53. 2014
    ..This study evaluated the potential clinical utility of the CCP test in a US-based clinical setting...